HealthKey vs Triomics (2026)
HealthKey and Triomics turn patient charts into trial candidate lists with evidence for research staff to review. HealthKey focuses on site prescreening across several study types; Triomics embeds oncology trial matching within a wider chart intelligence platform. HealthKey applies protocol criteria to structured EHR data, notes and incoming documents. Coordinators review ranked candidates and near matches through a dashboard or emailed updates. Oregon Urology Institute screened 5,360 patients against 24 prostate cancer trial criteria, with six full matches and 42 near matches. Other deployments cover obesity and rheumatoid arthritis. These case studies describe recruitment stages but do not measure eligible patients omitted by the software. Triomics Prism screens scheduled oncology patients against open trials daily and gives coordinators cited worklists. OncoLLM also supports Symphony for visit preparation and Harmony for registry abstraction, with connections to Epic, OncoEMR and iKnowMed. Its trial matching has peer reviewed evaluation, though each study covers particular institutions and protocols rather than all of them. HealthKey fits research practices and networks seeking protocol specific prescreening across community clinics and multiple therapeutic areas. Triomics fits cancer centers that want daily trial screening alongside oncology chart preparation and registry workflows. Both leave qualification with people who can examine the source evidence behind a proposed match.
- Prescreening spans multiple therapeutic areas and community clinics.
- Protocol criteria need application to notes and faxed documents.
- Coordinators want separate full and near match lists.
- The purchase centers on patient identification across sites and studies.
- Oncology trial screening should run against scheduled patients daily.
- Epic, OncoEMR or iKnowMed is the clinical environment.
- Trial matching should share models with visit preparation and registries.
- A cancer center wants cited chart evidence in its worklists.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. HealthKey and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | HealthKey | Triomics |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2021 |
| Headquarters | Austin, Texas | New York, New York, United States |
| Website | gethealthkey.com | triomics.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
HealthKey helps research practices find potential clinical trial participants in their existing patient records. Teams supply a protocol's inclusion and exclusion criteria, and the software applies those criteria across structured EHR fields, clinical notes, and documents such as faxed PDFs.
Source: AI Health Index, October 2026
Oncology AI that reads the whole patient chart. OncoLLM, a family of oncology-tuned models tuned further on each institution's records, reads every note, report, scan and fax and returns structured answers with a citation to the line in the chart behind each one.
Source: AI Health Index, October 2026
Questions buyers ask
How are HealthKey and Triomics priced and sold?
For HealthKey, implementation involves connecting the clinic's records and configuring the protocol's inclusion and exclusion logic, with support for research teams reviewing the results. The homepage's $0 upfront offer expired July 31, 2026, so its assigned values for implementation, setup of five trials, and support no longer describe current charges.
Triomics sells to cancer centers through a demo, as three products on one platform (Prism for trial matching, Symphony for visit preparation, Harmony for registry and quality work), and separately to life sciences companies for enrollment, feasibility, site identification and trial design. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
What evidence is published for HealthKey and Triomics?
In HealthKey's case, a May Flourish case describes 323 prescreen matches, 175 patients subsequently screened by coordinators, 74 passes, and two enrollments within 25 days.
For Triomics, the PRISM trial-matching system was published in npj Digital Medicine (October 2024), reporting 95 percent accuracy in matching patients to trials against expert review. An ASCO 2025 abstract co-authored with a leading academic medical center reports enterprise screening with OncoLLM producing 40 percent more trial matches and a 30 percent lift in trial accruals. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How much do HealthKey and Triomics leave to the clinician?
With HealthKey, the Flourish workflow similarly flagged boundary cases involving BMI, laboratory timing, or ambiguous history for manual review.
In Triomics' case, each value carries a citation that opens the source line in the chart, and audit trails are native. The company describes this as 'cited, auditable, never a black box', a claim about the basis of each output that the citations back up. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
HealthKey is based in Austin, Texas, and Triomics in New York. HealthKey describes success fees per patient without a public rate or current definition of success; its July 2026 upfront promotion has expired. Triomics has no public subscription price.